Skip to content

Gyre Therapeutics

Primary Menu

About
Science
Investors
Contact

Dose Selection For Subcutaneous Marzeptacog Alfa (Activated) In Subjects With Factor VII Deficiency Using Population Pharmacometric Clinical Trial Simulations

Post navigation

Previous: Subcutaneous Marzeptacog Alfa (Activated) Effectively Treats Bleeding in FVII Deficient Rats Both When Administered Prior To or After Bleeding Has Started

Next: Mitigation of Injection Site Reactions after Subcutaneous Administration of Dalcinonacog Alfa (DalcA) in Hemophilia B Using Preclinical Models

Search for:

Recent Comments

Archives

Categories

No categories

Meta

Log in
Entries feed
Comments feed
WordPress.org

About
- Management Team
- Board of Directors
Science
Investors
Contact

Gyre Therapeutics

Gyre Therapeutics, Inc.
| 12770 High Bluff Drive, Suite 150,
San Diego, CA 92130

© Gyre Therapeutics, Inc. All rights reserved.
Terms of Use Privacy Policy

X

Previous

Next